Satisfied Shareholders

Last time I created a new thread, I copped some heat but I don't want to conflate this discussion with other existing threads, so I apologise upfront, but I am curious as to what share price would satisfy shareholders, not now, but by years end, if a take over offer was tabled.

I am interested in what people think is a fair TO price and where they might get out. From my point of view:

• Pre 2591 results:

I think $50 is a fair offer and could see me cash in. It accounts for the remaining downside risks of sales not meeting targets and 2591 not passing phase 2 trials but also accounts for the upside opportunities of sales exceeding targets and 2591 passing phase 2 trials.

• Post 2591 results:

I find this really hard to quantify cause the current targeted markets are significantly larger than Retts. I have no backing for these figures but I would think that if ROW comes through, we could be looking at $25 a share and then if you were to go one further and hypothesise that all 4 trials are positive, then you would have to think the share price would easily, easily be north of $50. It would think that it is entirely possible that it could hit $50 on the back of just a couple of successful phase 2 trials, let alone 4..

If you go conservative and assume that the share price hits $50 after 4 successful phase 2 trials, then you would assume that the board would want a 100% premium, which brings us to $100 per share.

A $50 share price for a company that has Daybue being sold around the world and 4 successful phase 2 trials in 4 different conditions seems cheap, if you ask me but I don't know enough about how these things work and I guess I struggle to comprehend a $100 a share TO offer - but at the same time, I struggle to comprehend how you could not think it would be worth that (obviously factoring in the premium) given the upside.

Anyway, any thoughts would be most welcome.